Defining biological subsets in systemic lupus erythematosus: progress toward personalized therapy

Area of Science:

• Immunology
• Rheumatology
• Genetics

Background:

• Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease.
• Disease severity, treatment response, and organ damage vary significantly among patients.
• Pathogenesis involves complex immunological mechanisms influenced by genetic and environmental factors, with ancestral differences impacting SLE.

Purpose of the Study:

• To review recent developments in defining biological subsets of SLE.
• To explore how understanding SLE heterogeneity can personalize therapy.
• To highlight the significance of biological subsets in predicting treatment response.

Main Methods:

• Review of recent scientific literature on SLE pathophysiology and heterogeneity.
• Analysis of studies defining biological subsets within SLE patient populations.
• Examination of the role of type I interferon (IFN) levels in SLE subset identification.

Main Results:

• SLE exhibits significant heterogeneity across ancestral backgrounds, impacting genetics, immunology, and clinical features.
• Patients can be broadly categorized into high and low type I interferon (IFN) circulation groups, a distinction present across all ancestries.
• Differences in genetic factors, autoantibodies, and cytokine levels exist between high and low IFN SLE subsets.
• The high vs. low IFN classification has proven valuable in predicting response to anti-type I IFN therapies.

Conclusions:

• Biological subsets within SLE, such as those defined by type I IFN levels, are crucial for understanding disease pathophysiology.
• Recognizing SLE heterogeneity is essential for developing personalized therapeutic approaches.
• Further research into disease subsets will guide tailored treatments for improved patient outcomes.